title: Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
abstract: Immunomodulating gene therapy for the treatment of malignant diseases is under extensive investigation. In this study, we induced an antitumoral immune response with murine interleukin-12 (mIL-12) and murine granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor cells in a model of peritoneal carcinomatosis. Intraperitoneal injection of DHD/K12 tumoral cells engineered to produce IL-12 or GM-CSF did not generate any tumors, whereas untransduced DHD/K12 cells gave rise to peritoneal carcinomatosis. IL-12-expressing DHD/K12 cells also protected against tumors derived from coinjected parental cells. To test whether cytokine-producing cells could elicit a memory antitumoral immune response, animals received a challenge with parental DHD/K12 cells 35 days after the injection of proliferating or irradiated DHD/K12 engineered cells. Under our experimental conditions, irradiated tumor cells did not generate any antitumoral immunity. In contrast, tumor development was delayed and survival increased in the animals vaccinated with cytokine-secreting proliferating cells. A specific cytotoxic T-lymphocyte response against DHD/K12 parental cells was observed after vaccination with GM-CSF-expressing cells. Our results demonstrated that intraperitoneal vaccination with IL-12- or GM-CSF-expressing adenocarcinoma cells induced a systemic immune antitumoral response that may be useful as an adjuvant therapy after surgical resection of colorectal cancer.
authors.affiliation: Laboratory of Medical Chemistry and Medical Oncology, University of Liège, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Lechanteur
authors.forename: M
authors.initials: M
authors.lastname: Moutschen
authors.forename: F
authors.initials: F
authors.lastname: Princen
authors.forename: M
authors.initials: M
authors.lastname: Lopez
authors.forename: E
authors.initials: E
authors.lastname: Franzen
authors.forename: J
authors.initials: J
authors.lastname: Gielen
authors.forename: V
authors.initials: V
authors.lastname: Bours
authors.forename: M P
authors.initials: MP
authors.lastname: Merville
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000818:Animals; D019496:Cancer Vaccines; D003110:Colonic Neoplasms / Q000628:therapy*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D018664:Interleukin-12 / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000517:prevention & control / Q000628:therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012190:Retroviridae / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D019496:Cancer Vaccines; D018664:Interleukin-12; D016178:Granulocyte-Macrophage Colony-Stimulating Factor